PT - JOURNAL ARTICLE AU - van der Putten, Boas C.L. AU - Vlaminckx, Bart J.M. AU - de Gier, Brechje AU - Freudenburg-de Graaf, Wieke AU - van Sorge, Nina M. TI - Group A streptococcal meningitis with the M1<sub>UK</sub> variant in the Netherlands AID - 10.1101/2023.02.27.23286423 DP - 2023 Jan 01 TA - medRxiv PG - 2023.02.27.23286423 4099 - http://medrxiv.org/content/early/2023/03/21/2023.02.27.23286423.short 4100 - http://medrxiv.org/content/early/2023/03/21/2023.02.27.23286423.full AB - We analyzed over 40 years of bacteriological surveillance data to reveal a 4-fold increase in Group A streptococcal (GAS) meningitis in 2022 compared to the annual average of 1982-2021 (n=5/year). Already 10 GAS meningitis cases occurred in 2023 (until March 13th). Molecular typing revealed that 25 out-of-29 (86%) isolates received in 2022 and 2023 were emm1.0 (Figure 1). WGS analysis of 19 emm1.0 isolates (2019 until 20th December 2022) demonstrated that 15 out-of-19 (79%) isolates belonged to the toxicogenic M1UK lineage. Based on these observations, we urge clinicians to be vigilant regarding clinical sign of meningitis with invasive GAS infections, since this disease manifestation appears to have a higher than expected occurrence due to clonal replacement by the recently-emerged M1UK variant.Competing Interest StatementNMvS declares fee for service and consultancy fees directly paid to the institution from MSD and GSK outside the submitted work. NMvS declared royalties related to a patent (WO 2013/020090 A3) on vaccine development against Streptococcus pyogenes (Vaxcyte; Licensee: University of California San Diego with NMvS as co-inventor). NMvS is a member of the Science advisory Board for the ItsME foundation (unpaid) and Rapua te me ngaro ka tau project (paid to institution; Project facilitating Strep A vaccine development for Aotearoa New Zealand). Other authors declare no conflict of interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe mentioned strains are available upon request to the authors.